Gynecological Cancers Publications by UCSD Radiation Oncology Faculty
Listed below are Gynecologic Cancer Articles published by members of the UCSD Department of Radiation Oncology:
Mell LK, Mundt AJ. Intensity-modulated radiation therapy in gynecologic cancers: growing support, growing acceptance. Cancer J 2008:14:198-199
Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JCm Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:1504-1508
Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:428-34
Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF, Gynecologic Oncology Group. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:3-9
Turina M, Mulhall AM, Mahid SS, Yashar C, Galandiuk S. Frequency and surgical management of chronic complications related to pelvic radiation. Arch Surg 2008;143:46-52
Carrascosa LA, Yashar CM, Paris KJ, Larocca RV, Faught SR, Spanos WJ. Palliation of pelvic and head and neck cancer with paclitaxel and a novel radiotherapy. J Palliat Med 2007;10:877-8
Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:1356
Aydogan B, Wang S, Smith B, Mundt AJ, et al. A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients. Int J Radiat Oncol Biol Phys 2006;65:266
Kochanski JD, Mell LK, Roeske JC, Mundt AJ. Intensity modulated radiation therapy in gynecologic malignancies: current status and future directions. Clin Adv Hem Oncol 2006:4:379-386
Salama JK, Mundt AJ, et al. Preliminary outcome and toxicity report of extended field intensity modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006;65:1170-6
Xia D, Roeske JC, Yu L, Pelizzari CA, Mundt AJ, et al. A hybrid approach to reducing computed tomography metal artifacts in intracavitary brachytherapy. Brachytherapy 2005;4:18
Saxena A, Yashar CM, et al. Cellular response to chemotherapy and radiation in cervical cancer. Am J Obstet Gynecol 2005;192: 1399
Burke T, Muggia F, Mundt AJ. Uterine Cancer. In: Devita V, Hellman S, Rosenberg (eds). Principles and Practice of Oncology. Williams and Wilkins, Baltimore, 2005
Fleming GF, Montag AC, Mundt AJ, et al. Uterine Malignancies. In: Chang AE, Ganz PA, Hayes DF et al. (Editors). Oncology: An Evidence-Based Approach. Blackwell Publishing Ltd, Oxford, 2005
Yashar CM, Spanos WJ, Taylor DD, Gercel-Taylor C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gyn Onc 2005;99:199
Haslam JJ, Lujan AE, Mundt AJ, et al. Setup errors in patients treated with intensity modulated whole pelvic radiation therapy for gynecological malignancies. Med Dosim 2005;30:36
Schroder M, Mell LK, Hurteau JA, Collins YC, Rotmensch J, Waggoner SE, Yamada SD, Small W, Mundt AJ. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys 2005;61:1078
Roeske JC, Lujan A, Reba RC, Penney BC, Yamada SD, Mundt AJ. Incorporation of SPECT bone marrow imaging in intensity modulated whole pelvic radiation therapy treatment planning for gynecologic malignancies. Radiother Oncol 2005;77:11
Mundt AJ, et al. Phase I trial of concomitant vinorelbine, cisplatin and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol 2004;92:801
Salama JK, Roeske JC, Mehta N, Mundt AJ. Intensity modulated radiotherapy therapy in gynecologic malignancies. Curr Treat Options Oncol 2004;5:97
Citron J, Mundt AJ. Pathologic stage I-II endometrial cancer in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys 2004;59:1432
Rowinsky E, Mundt AJ. 21st Century Innovative Therapies. In: Hoskins WJ, Perez CA, Young RC (eds). Principles and Practice of Gynecologic Oncology. J.B. Lippincott, Philadelphia, 2004
Mell LK, Meyer JJ, Tretiakova M, Kramtsov A, Gong C, Yamada SD, Montag AG, Mundt AJ. Prognostic significance of E-cadherin protein expression in pathologic stage I-III endometrial cancer. Clin Cancer Res 2004;10:5546
Murphy K, Rotmensch J, Yamada SD, Mundt AJ. Patterns of failure and outcome of clear cell carcinoma of the uterus: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;55:1272
Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in patients with gynecologic malignancies treated with intensity modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2003;56:1354
Mell LK, Mundt AJ. Concern with "Is there a survival benefit to adjuvant radiotherapy in high-risk surgical stage I endometrial cancer?" (Letter to the Editor). Gynecol Oncol 2003;90:499
Lujan AE, Mundt AJ, et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:516.
Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003;57:1004
Roeske JC, Bonta D, Lujan AE, Mell LK, Yamada SD, Rotmensch J, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 2003;69:201
Roeske JC, Lund C, Pelizzari CA, Pan X, Mundt AJ. Reduction of computed tomography metal artifacts due to the Fletcher-Suit applicator in gynecology patients receiving intracavitary brachytherapy. Brachytherapy 2003;2:207
Mundt AJ, et al. Intensity modulated whole pelvic radiation therapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;2:1330
Mundt AJ, et al. Intensity-modulated radiation therapy in gynecologic malignancies. Med Dosim 2002;27:131
Mundt AJ, et al. Treatment of Recurrent Endometrial Cancer: Chemotherapy, Hormonal therapy, and Radiation Therapy. In: Gershenson, Gore, McGuire, Quinn, Thomas (eds). Gynecologic Cancer: Controversies in Management. Elsevier Science (USA), Philadephia, 2002
Brixey C, Roeske JC, Lujan AE, Mundt AJ. Impact of intensity modulated whole pelvic radiation therapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;54:1388
Mundt AJ, et al.. Can intensity modulated radiation therapy replace brachytherapy in the treatment of patients with cervical cancer? Point. Brachytherapy 2002;1:192
Mundt AJ. Commentary on “Postoperative pelvic radiotherapy improved locoregional control but not survival in stage I endometrial carcinoma” Creutzberg CL, van Putten WLJ, Koper PCM, et al. Lancet 2000;355:1404-1411. Evidence-based Obstet Gynecol 2001;3:46
Mundt AJ, et al. Phase I trial of concomitant vinorelbine, paclitaxel and pelvic radiation therapy for cervical cancer and other advanced pelvic malignancies. Gynecol Oncol 2001;82:333
Ashman JA, Connell PP, Rotmensch J, Waggoner S, Yamada SD, Mundt AJ. Outcome and management of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001;82:338
Mundt AJ, et al. Pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients following adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:1145
Mundt AJ, et al. Surgery and postoperative radiation therapy in FIGO stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys 2001;50:1154
Mundt AJ, et al. Initial clinical experience using intensity modulated whole pelvic radiation therapy for gynecologic malignancies. Gynecol Oncol 2001;82:456
Phelan C, Montag A, Rotmensch J, Yamada SD, Waggoner SE, Mundt AJ. Outcome and management of pathologic stage I endometrial cancer patients with involvement of the lower uterine segment. Gynecol Oncol 2001;83:513
Wollschlaeger K, Connell, PP, Waggoner S, Rotmensch J, Mundt AJ. Acute problems during low-dose-rate intracavitary brachytherapy for cervical carcinoma. Gynecol Oncol 2000;76:67
Tran BN, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. Am J Clin Oncol 2000;23:476
Mundt AJ, et al. Do conventional pathologic features lose their prognostic significance following postoperative radiation therapy in pathologic stage 1-II endometrial carcinoma? Int J Cancer 2000;90:224
Castro IN, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. Synchronous ovarian and endometrial malignancies. Am J Clin Oncol 2000;23:521
Rotmensch J, Connell PP, Yamada D, Waggoner SE, Mundt AJ. One versus two intracavitary brachytherapy applications in early stage cervical cancer patients undergoing definitive radiation therapy. Gynecol Oncol 2000;78:32
Mundt AJ, et al. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol 2000;79:79
Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ. Intensity modulated whole pelvic radiation therapy in patients with gynecological malignancies. Int J Radiat Oncol Biol Phys 2000;48:1613
Connell PP, Rotmensch J, Waggoner S, Mundt AJ. Significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999;74:74
Connell PP, Waggoner S, Rotmensch J, Mundt AJ. Race and clinical outcome in endometrial carcinoma. Obstet Gynecol 1999;94:713
Calvin D, Connell PP, Rotmensch J, Waggoner S, Mundt AJ. Surgery and adjuvant radiation therapy in stage II endometrial carcinoma. Am J Clin Oncol 1999;22:238
Mundt AJ, et al. Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies. Gynecol Oncol 1999;72:45
Mundt AJ, et al. Preoperative intracavitary brachytherapy in early stage cervical carcinoma, Am J Clin Oncol 1999;22:737
Weiss M, Connell P, Rotmensch J, Waggoner S, Mundt AJ. External pelvic radiation therapy in stage IC endometrial carcinoma, Obstet Gynecol 1999;93:599
Mitchell PA, Rotmensch J, Waggoner S, Mundt AJ. Radiation therapy in elderly patients with cervical carcinoma. Gynecol Oncol 1998;71:291
Mundt AJ, et al. Race and clinical outcome in patients with cervical carcinoma undergoing radiation therapy. Gynecol Oncol 1998;71:151
Roeske J, Mundt AJ. et al. Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis. Int J Radiat Oncol Biol Phys 1997;37:351
Shields LB, Gercel-Taylor C, Yashar CM, et al. Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig 1997;4:298
Yashar CM, et al. Lymophokine-activated killer (LAK)-mediated lysis of sequentially isolated ovarian cancer cell lines. Am J Reprod Immunol 1997;38:431
Pearl ML, Yashar CM, et al. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gyn Onc 1994;53:339
Sharma S, Singhal S, Sandhu APS, et al. Local thermoradiotherapy in carcinoma cervix : Improved local control versus increased incidence of distant metastasis. Asia - Oceania J Obstet Gynaecol 1991;17:5